Vascular disrupting agents in clinical development
Currently, ZD6126 is being explored in metastatic renal-cell carcinoma. ABT-751. ABT-751 is a sulphonamide molecule that can be given orally, and has shown ...
http://www.nature.com/bjc/journal/v96/n8/full/6603694a.html...
|
Federal
Irinotecan in Metastatic, EGFR-Positive Colorectal Carcinoma, 3500 ... 44, Quinn , David, Astra Zeneca, ZD6126 in Metastatic Renal Cell Carcinoma (Stage IV) ...
http://www.usc.edu/schools/medicine/departments/medicine/div...
|
Efficacy of combined antiangiogenic and vascular disrupting agents ...
... of human renal cell carcinoma (Caki-1) and Kaposi's sarcoma (KSY-1). ... When ZD6126 and ZD6474 were combined, the tumor growth delays increased to 55
...
http://www.ncbi.nlm.nih.gov/pubmed/15519796...
|
Nature Clinical Practice Oncology | Drug Insight: vascular ...
Figure 4 Preclinical human models of human renal cell carcinoma in nude mice ..... (2002) Antitumor activity of the novel vascular targeting agent ZD6126 in
...
http://www.nature.com/ncponc/journal/v3/n12/full/ncponc0663....
|
ZD-6126 AstraZeneca Jens Soltau & Joachim Drevs
human renal cell carcinoma (Caki-1) and Kaposi's sarcoma ...... METASTASIS 2002 19 Abs A25. 510275 Anti-vascular effects of ZD6126 and the enhancement of ...
http://www.biomedcentral.com/content/pdf/cd-528899.pdf...
|
British Journal of Cancer - Circulating endothelial cells in ...
27 May 2008 ... In contrast, a study on the VDA ZD6126 demonstrated a .... Figlin RA (2007) Sunitinib vs interferon alfa in metastatic renal-cell carcinoma. ...
http://www.nature.com/bjc/journal/v98/n11/full/6604383a.html...
|
Predicting Benefit from Anti-angiogenic Agents in Malignancy
30 Aug 2006 ... Expression of the angiogenic factors vascular endothelial cell growth factor, .... in patients with metastatic renal cell carcinoma. ...
http://www.medscape.com/viewarticle/543762...
|
British Journal of Cancer - Table of Contents
Selective bladder preservation for muscle-invasive transitional cell carcinoma of ... Ki-67 (MIB-1) in patients with metastatic renal cell carcinoma FREE ...
http://www.nature.com/bjc/journal/v90/n3/index.html...
|
Antitumor efficacy of conventional anticancer drug...[Int J Radiat ...
Tumor response to treatment was assessed by clonogenic cell survival. RESULTS: Treatment with ZD6126 was found to damage existing neovasculature, ...
http://www.ncbi.nlm.nih.gov/pubmed/12459379...
|
Role of novel targeted therapies in the clinic
Preclinical evaluation of the vascular-disrupting agent ZD6126 has shown ..... BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory ...
http://www.nature.com/bjc/journal/v92/n1s/full/6602605a.html...
|
